ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1
Biochemical Journal · 2023
DOI: 10.1042/bcj20220598 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, 2023. Verfasst von Kathryn Balmanno und 6 weiteren Autor:innen. Beteiligte Einrichtung: Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, U.K. Hauptthemen laut MEDLINE: MAP Kinase Signaling System, Proteasome Endopeptidase Complex. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
Innate or acquired resistance to small molecule BRAF or MEK1/2 inhibitors (BRAFi or MEKi) typically arises through mechanisms that sustain or reinstate ERK1/2 activation. This has led to the development of a range of ERK1/2 inhibitors (ERKi) that either inhibit kinase catalytic activity (catERKi) or additionally prevent the activating pT-E-pY dual phosphorylation of ERK1/2 by MEK1/2 (dual-mechanism or dmERKi). Here, we show that eight different ERKi (both catERKi or dmERKi) drive the turnover of ERK2, the most abundant ERK isoform, with little or no effect on ERK1. Thermal stability assays show that ERKi do not destabilise ERK2 (or ERK1) in vitro, suggesting that ERK2 turnover is a cellular consequence of ERKi binding. ERK2 turnover is not observed upon treatment with MEKi alone, suggesting it is ERKi binding to ERK2 that drives ERK2 turnover. However, MEKi pre-treatment, which blocks ERK2 pT-E-pY phosphorylation and dissociation from MEK1/2, prevents ERK2 turnover. ERKi treatment of cells drives the poly-ubiquitylation and proteasome-dependent turnover of ERK2 and pharmacological or genetic inhibition of Cullin-RING E3 ligases prevents this. Our results suggest that ERKi, including current clinical candidates, act as ‘kinase degraders’, driving the proteasome-dependent turnover of their major target, ERK2. This may be relevant to the suggestion of kinase-independent effects of ERK1/2 and the therapeutic use of ERKi.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Signalling Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, U.K.
- Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, U.K.
ORCID-Profile: Simon J Cook
Förderung
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Balmanno, K., Kidger, A. M., Byrne, D. P., Sale, M. J., Nassman, N., Eyers, P. A., & Cook, S. J. (2023). ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1. Biochemical Journal. https://doi.org/10.1042/bcj20220598
Vancouver
Balmanno K, Kidger AM, Byrne DP, Sale MJ, Nassman N, Eyers PA, et al. ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1. Biochemical Journal. 2023. doi:10.1042/bcj20220598
BibTeX
@article{Balmanno2023,
author = {Balmanno, Kathryn and Kidger, Andrew M and Byrne, Dominic P and Sale, Matthew J and Nassman, Nejma and Eyers, Patrick A and Cook, Simon J},
title = {ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1},
journal = {Biochemical Journal},
year = {2023},
doi = {10.1042/bcj20220598}
}
EUVIMED